Translational Development Acquisition Corp. (TDAC) Stock Price & Analysis
Translational Development Acquisition Corp. (TDAC) fell 0.09% to USD 10.74 as of July 25, 2026 at 08:29 UTC, according to Nexqual real-time market data.
TDAC last closed at USD 10.74; the session ranged USD 10.74–10.74 on volume of 1,484 shares. Market capitalization is $207.28M, with a 52-week range of USD 10.32–10.8 (NGM). Source: Nexqual, July 25, 2026 at 08:29 UTC.
Key Statistics (as of July 25, 2026 at 08:29 UTC)
| Price | USD 10.74 |
|---|---|
| Change | ▼ 0.09% (down) |
| Previous Close | USD 10.74 |
| Open | USD 10.74 |
| Day Range | USD 10.74 – 10.74 |
| 52-Week Range | USD 10.32 – 10.8 |
| Volume | 1,484 shares |
| Market Cap | $207.28M |
| Exchange | NGM |
Technical Analysis (TDAC)
Nexqual's technical model rates TDAC "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 08:29 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.24 (neutral) |
| vs SMA50 | Above (USD 10.71) |
| MACD | 0.01 (positive) |
Analyst Ratings (TDAC)
Wall Street analysts rate TDAC "None", per Nexqual as of July 25, 2026 at 08:29 UTC.
| Consensus Rating | None |
|---|
Earnings (TDAC)
Source: Nexqual, July 25, 2026 at 08:29 UTC.
Financials & Fundamentals (TDAC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.09 |
| Total Cash | $24,630 |
| Total Debt | $500,000 |
| Free Cash Flow | $-352,611 |
Source: Nexqual, July 25, 2026 at 08:29 UTC.
Financial Health Score (TDAC)
Nexqual rates Translational Development Acquisition Corp.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 08:29 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $25K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$682K |
| Efficiency | Mixed — No data |
Ownership (TDAC)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +86.81% |
| Shares Outstanding | 19.31M |
| Float | 15.95M |
| Short % of Float | +0.03% |
Source: Nexqual, July 25, 2026 at 08:29 UTC.
Leadership (TDAC)
Translational Development Acquisition Corp. is led by Michael M. B. Hoffman (age 75), Chairman of the Board & CEO, per Nexqual as of July 25, 2026 at 08:29 UTC.
| Chairman of the Board & CEO | Michael M. B. Hoffman (age 75) |
|---|---|
| Chief Financial Officer | Avi C. Das |
Major Backers & Investors (TDAC)
Notable institutional backers of Translational Development Acquisition Corp. include Magnetar Financial LLC, Wolverine Asset Management, LLC, AQR Arbitrage LLC, according to Nexqual as of July 25, 2026 at 08:29 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Magnetar Financial LLC | 7.54% |
| Wolverine Asset Management, LLC | 7.25% |
| AQR Arbitrage LLC | 6.34% |
| LMR Partners LLP | 4.64% |
| Hudson Bay Capital Management Lp | 3.77% |
| Tenor Capital Management Co., L.p. | 3.68% |
| Karpus Management, Inc. | 3.5% |
| Alberta Investment Management Corp | 3.48% |
Source: Nexqual, July 25, 2026 at 08:29 UTC.
From Translational Development Acquisition Corp.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Translational Development Acquisition Corp. does not have significant operations.
- The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GIX | GigCapital9 Corp. | USD 9.94 | ▲ 0% |
| FUSE | Fusemachines Inc. | USD 0.88 | ▼ 4.86% |
| APXT | Apex Treasury Corporation | USD 10.13 | ▼ 0.21% |
| TDACW | Trident Acquisitions Corp. | USD 1.77 | ▲ 15.69% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:29 UTC. This page is informational and not investment advice.